| 001 | 163659 | ||
| 005 | 20240229133510.0 | ||
| 024 | 7 | _ | |a 10.1007/s00066-020-01684-y |2 doi |
| 024 | 7 | _ | |a pmid:32970162 |2 pmid |
| 024 | 7 | _ | |a 0039-2073 |2 ISSN |
| 024 | 7 | _ | |a 0179-7158 |2 ISSN |
| 024 | 7 | _ | |a 1439-099X |2 ISSN |
| 037 | _ | _ | |a DKFZ-2020-01936 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Ebert, Nadja |0 P:(DE-He78)8bff76ab3cfe753721744ece2dfa32e5 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Results of a randomized controlled phase III trial: efficacy of polyphenol-containing cystus® tea mouthwash solution for the reduction of mucositis in head and neck cancer patients undergoing external beam radiotherapy. |
| 260 | _ | _ | |a Heidelberg |c 2021 |b Springer Medizin |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1679390929_27551 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:E220#LA:E220#2021 Jan;197(1):63-73 |
| 520 | _ | _ | |a To determine the effect of Cystus® tea (Naturprodukte Dr. Pandalis GmbH & Co. KG) as mouthwash compared to sage tea on oral mucositis in patients undergoing radio(chemo)therapy for head and neck cancer.In this randomized, prospective phase III study, 60 head and neck cancer patients with primary or postoperative radio(chemo)therapy were included between 04/2012 and 06/2014. They received either sage or Cystus® tea for daily mouthwash under therapy. Mucositis was scored twice a week following the Radiation Therapy Oncology Group and the European Organization for Research and Treatment Cancer (RTOG/EORTC) scoring system. Dental parameters were also recorded. Statistical evaluation of the primary endpoint was performed using t‑test and log rank test.Data from 57 patients could be evaluated. Patient characteristics showed no significant difference between the two groups (n = 27 sage; n = 30 Cystus®). A total of 55 patients received the prescribed dose (60-66 Gy postoperative; 70-76.8 Gy primary). Mucositis grade 3 was observed in 23 patients (n = 11 sage; n = 12 Cystus®) and occurred between day 16 and 50 after start of therapy. There was no significant difference between the two groups in latency (p = 0.75) and frequency (p = 0.85) of the occurrence of mucositis grade 3. The self-assessment of the oral mucosa and the tolerability of the tea also showed no significant differences. Occurrence of dental pathologies appeared to increase over time after radiotherapy.Cystus® and sage tea have a similar effect on the occurrence of radiation-induced mucositis regarding latency and incidence. Cystus® tea mouthwash solution is tolerated well and can be applied in addition to intensive oral care and hygiene along with the application of fluorides. |
| 536 | _ | _ | |a 315 - Bildgebung und Radioonkologie (POF4-315) |0 G:(DE-HGF)POF4-315 |c POF4-315 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Kensche, Anna |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Löck, Steffen |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Hadiwikarta, Wahyu Wijaya |0 P:(DE-He78)f3a873e7ab94ef36c11fcf1023c8d860 |b 3 |u dkfz |
| 700 | 1 | _ | |a Hänsch, Anna |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Dörr, Wolfgang |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Krause, Mechthild |0 P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9 |b 6 |u dkfz |
| 700 | 1 | _ | |a Hannig, Christian |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Baumann, Michael |0 P:(DE-He78)933f7d725ac87378f459623783585a1f |b 8 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1007/s00066-020-01684-y |0 PERI:(DE-600)2003907-4 |n 1 |p 63-73 |t Strahlentherapie und Onkologie |v 197 |y 2021 |x 1439-099X |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:163659 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)8bff76ab3cfe753721744ece2dfa32e5 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)f3a873e7ab94ef36c11fcf1023c8d860 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)933f7d725ac87378f459623783585a1f |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-315 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Bildgebung und Radioonkologie |x 0 |
| 913 | 0 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-319H |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Addenda |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2020-01-14 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2020-01-14 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2020-01-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2020-01-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |d 2020-01-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2020-01-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2020-01-14 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |d 2020-01-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2020-01-14 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |d 2020-01-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2020-01-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2020-01-14 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2020-01-14 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b STRAHLENTHER ONKOL : 2018 |d 2020-01-14 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2020-01-14 |
| 920 | 2 | _ | |0 I:(DE-He78)E220-20160331 |k E220 |l E220 Radioonkologie Radiobiologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)DD01-20160331 |k DD01 |l DKTK DD zentral |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)E220-20160331 |k E220 |l E220 Radioonkologie Radiobiologie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)M010-20160331 |k M010 |l M010 Stiftungsvorstand |x 2 |
| 920 | 0 | _ | |0 I:(DE-He78)E220-20160331 |k E220 |l E220 Radioonkologie Radiobiologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)DD01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E220-20160331 |
| 980 | _ | _ | |a I:(DE-He78)M010-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::